1. Home
  2. MRDN vs IPHA Comparison

MRDN vs IPHA Comparison

Compare MRDN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meridian Holdings Inc. Common Stock

MRDN

Meridian Holdings Inc. Common Stock

HOLD

Current Price

$10.07

Market Cap

155.1M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.57

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRDN
IPHA
Founded
N/A
1999
Country
United States
France
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.1M
165.3M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
MRDN
IPHA
Price
$10.07
$1.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $19.73
$6.67
AVG Volume (30 Days)
★ 33.8K
32.9K
Earning Date
11-02-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.35
N/A
Revenue
★ $182,863,373.00
N/A
Revenue This Year
$12.08
$390.56
Revenue Next Year
$10.93
$143.06
P/E Ratio
$31.06
★ N/A
Revenue Growth
★ 21.01
N/A
52 Week Low
$6.01
$1.17
52 Week High
$16.09
$2.71

Technical Indicators

Market Signals
Indicator
MRDN
IPHA
Relative Strength Index (RSI) 30.15 41.16
Support Level $9.99 $1.36
Resistance Level $14.76 $1.57
Average True Range (ATR) 0.56 0.09
MACD -0.02 0.02
Stochastic Oscillator 10.34 32.14

Price Performance

Historical Comparison
MRDN
IPHA

About MRDN Meridian Holdings Inc. Common Stock

Meridian Holdings Inc is engaged in the online gaming and betting business, providing sports betting, online casino, and gaming operations across multiple jurisdictions in Europe, Africa, and Central and South America. The company has three reportable segments: MeridianBet Group, GMAG, and RKings & CFAC. The MeridianBet Group segment includes retail and online sports betting, casinos, and related gaming operations. The GMAG segment focuses on the resale of third-party gaming content, mainly serving customers in the Asia-Pacific region. The RKings & CFAC segment is involved in pay-to-enter prize competitions and trade promotions conducted in the United Kingdom and Australia. It generates the majority of its revenue from the MeridianBet Group segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: